Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | SPR | P35270 | 3/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.35 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.35 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2840643 | 0.71 | — | — | |
| SCHEMBL383127 | 0.69 | KMT2A (0.44) | PDPK1PARP1MAPTSPRADORA2A | |
| SCHEMBL15668178 | 0.69 | PDPK1 (0.39) | PDPK1PARP1ADORA2AADORA1MEN1 | |
| SCHEMBL209626 | 0.67 | PDPK1 (1.00) | PDPK1PARP1SMN1; SMN2RAB9AMAPT | |
| SCHEMBL2447243 | 0.65 | CXCR2 (0.36) | — | |
| Hydrochloric Acid SCHEMBL30700362 | 0.65 | PDPK1 (0.96) | PDPK1PARP1SMN1; SMN2RAB9AMAPT | |
| SCHEMBL15668177 | 0.65 | PDPK1 (0.38) | PDPK1PARP1ADORA2AADORA1MEN1 | |
| SCHEMBL20458007 | 0.64 | SMN1; SMN2 (0.54) | PDPK1PARP1SMN1; SMN2RAB9AMAPT | |
| SCHEMBL5068159 | 0.64 | SMN1; SMN2 (0.54) | PDPK1PARP1SMN1; SMN2RAB9AMAPT | |
| SCHEMBL17893461 | 0.64 | SMN1; SMN2 (0.54) | PDPK1PARP1SMN1; SMN2RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228499-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2024-07-11 | — | — | US | disclosed |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240210408-A1 | USE OF DIVALENT METALS FOR ENHANCEMENT OF FLUORESCENT SIGNALS | SONY GROUP CORP (JP) | 2024-06-27 | — | — | US | disclosed |
| US-20240207423-A1 | PROGAMMABLE POLYMERIC DRUGS | SONY GROUP CORP (JP) | 2024-06-27 | — | — | US | disclosed |
| US-12018159-B2 | Ultra bright dimeric or polymeric dyes and methods for preparation of the same | Sony Group Corporation (JP) | 2024-06-25 | — | — | US | disclosed |
| US-12006438-B2 | Polymeric dyes with linker groups comprising deoxyribose | Sony Group Corporation (JP) | 2024-06-11 | — | — | US | disclosed |
| WO-2024118840-A1 | FUSED PYRIMIDINES AS MASP-2 INHIBITORS | OMEROS CORPORATION (US) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024110803-A1 | POLYMERIC COMPOUNDS COMPRISING ANTINEOPLASTIC AGENTS | Sony Group Corporation (JP) | 2024-05-30 | — | — | WO | disclosed |
| US-11981820-B2 | Ultra bright dimeric or polymeric dyes | Sony Group Corporation (JP) | 2024-05-14 | — | — | US | disclosed |
| US-20240132725-A1 | SPACING LINKER GROUP DESIGN FOR BRIGHTNESS ENHANCEMENT IN DIMERIC OR POLYMERIC DYES | Sony Group Corporation (JP) | 2024-04-25 | — | — | US | disclosed |
| WO-2013064984-A1 | BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013064983-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2013-05-10 | — | — | WO | disclosed |
| US-8415370-B2 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2013-04-09 | — | — | US | disclosed |
| US-20120295897-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2012-11-22 | — | — | US | disclosed |
| US-8263606-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-09-11 | — | — | US | disclosed |
| US-8101647-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-01-24 | — | — | US | disclosed |
| US-20110144139-A1 | HEPSIN INHIBITORS | FRED HUTCHINSON CANCER RESEARCH CENTER | 2011-06-16 | — | — | US | disclosed |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-03 | — | — | US | disclosed |
| WO-2009151920-A2 | HEPSIN INHIBITORS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2008147864-A2 | METHODS OF USING PIPERAZINE COMPOUNDS IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228499-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, SPINT2, SERPINB1 | PDPK1 2336/4885PARP1 743/4885SMN1; SMN2 3397/4885 |
| US-11981820-B2 | Ultra bright dimeric or polymeric dyes | IK, MRPS2, UFM1 | PDPK1 4357/4885PARP1 1015/4885SMN1; SMN2 1068/4885 |
| US-20110144139-A1 | HEPSIN INHIBITORS | HPN, TMPRSS2, SPINT2 | PDPK1 2660/4885PARP1 2174/4885SMN1; SMN2 4667/4885 |
| US-20240207423-A1 | PROGAMMABLE POLYMERIC DRUGS | OPRM1, CHRM1, TUBB3 | PDPK1 3126/4885PARP1 2171/4885SMN1; SMN2 1818/4885 |
| US-12006438-B2 | Polymeric dyes with linker groups comprising deoxyribose | H1-0, POLM, H1-2 | PDPK1 3252/4885PARP1 170/4885SMN1; SMN2 1000/4885 |
| US-20120295897-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | TRPV3, TRPC3, TRPV1 | PDPK1 2108/4885PARP1 3975/4885SMN1; SMN2 272/4885 |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | PDPK1 2005/4885PARP1 3928/4885SMN1; SMN2 289/4885 |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | PDPK1 1911/4885PARP1 2076/4885SMN1; SMN2 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.